Methazolamide‐induced toxic epidermal necrolysis in a man carrying <scp>HLA</scp>‐B*59:01: successful treatment with infliximab and glucocorticoid

Jiang, Yanyun; Nguyen, Giang Huong; Jin, Hongzhong

doi:10.1111/ijd.13924

Cited by 10 publications

(5 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 42 ] Switzerland Case report TEN 1 Infliximab – – Jiang et al. [ 43 ] China Case report TEN 1 Infliximab Corticosteroids + supportive therapy After Kherlopian et al. [ 12 ] Australia Case series TEN 4 Adalimumab – – Kreft et al.…”

Section: Resultsmentioning

confidence: 99%

“…This meta-analysis has identified 22 publications (made up of 31 patients) that use infliximab for the treatment of SJS-TEN overlap and TEN. Patient-level analysis revealed that infliximab had comparable efficacy to etanercept in treating patients with TEN, as indicated by similar clinical outcomes, including time to reepithelialization, hospitalization time, and mortality rate (Table 1 ) Infliximab was the first TNF-α inhibitor proven to be effective in treating TEN [ 37 ], however, recent publications regarding its use are lacking, with only seven cases reported between 2015 and 2022 [ 15 , 25 , 26 , 43 , 46 , 63 , 64 ]. In 2004, Paquet et al.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Biologic TNF-α Inhibitors for Stevens–Johnson Syndrome, Toxic Epidermal Necrolysis, and TEN-SJS Overlap: A Study-Level and Patient-Level Meta-Analysis

Cao

Zhang

Xing

et al. 2023

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Introduction Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe cutaneous adverse reactions with high morbidity and mortality and not clearly established treatment protocol. This meta-analysis aimed to evaluate the efficacy and safety of three biologic TNF-α inhibitors (infliximab, etanercept, adalimumab) in the treatment of SJS, SJS-TEN overlap, and TEN. Methods Electronic databases were searched for original studies containing human participants diagnosed with SJS/TEN and treated with biologic TNF-α inhibitors. Individual patient data were collected and summarized to provide a comprehensive overview on therapeutic efficacy of different biologic TNF-α inhibitors for SJS, SJS-TEN overlap, and TEN, respectively. Meta-analyses on aggregated study data were conducted using random-effects model. Results Overall, 55 studies with 125 sets of individual patient data were included. Infliximab was used to treat 3 patients with SJS-TEN overlap and 28 patients with TEN, and the actual mortality rate was 33.3% and 17%, respectively. Etanercept was administered to 17 patients with SJS, 9 patients with SJS-TEN overlap, and 64 patients with TEN, and mortality rate was reported to be 0%, 0%, and 12.5%, respectively. For participants with TEN, no significant difference was found in time of reepithelialization, hospitalization time, and mortality rate comparing etanercept with infliximab. More sequelae were reported in patients receiving infliximab than in patients treated with etanercept (39.3% versus 6.4%). Adalimumab was administered to four patients with TEN, and mortality rate was 25%. Meta-analyses on aggregated study data revealed significantly shortened hospitalization time in etanercept compared with non-etanercept groups [weighted mean differences (WMD) −5.30; 95% confidence interval (CI) −8.65 to −1.96]. Etanercept was associated with a survival benefit for patients when compared with non-etanercept treatment, however, the analysis was not statistically significant (odds ratio 0.55; 95% CI 0.23–1.33). Conclusions On the basis of the current findings, etanercept is currently the most promising biologic therapy for SJS/TEN. Further evaluation in prospective studies is required to confirm its efficacy and safety. Supplementary Information The online version contains supplementary material available at 10.1007/s13555-023-00928-w.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Biologic TNF-α Inhibitors for Stevens–Johnson Syndrome, Toxic Epidermal Necrolysis, and TEN-SJS Overlap: A Study-Level and Patient-Level Meta-Analysis

Cao

Zhang

Xing

et al. 2023

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

show abstract

“…Patients harbouring HLA-B*59:01 or HLA-B*59:01–C*01:02 haplotypes are at increased risk of methazolamide-induced Stevens-Johnson syndrome/toxic epidermal necrolysis 6. This finding has been reported in Asian patients, with no similar reports in Caucasians 6 7…”

Section: Introductionmentioning

confidence: 93%

Association of HLA-C*01:02 with methazolamide-induced toxic epidermal necrolysis

Chen

et al. 2022

BMJ Case Rep

View full text Add to dashboard Cite

show abstract

“…Few case reports have described the use of combination therapy with anti-TNF-α and corticosteroids [ 95 , 96 , 97 , 98 , 99 , 100 , 101 , 102 , 103 ]. In 2021, Sachdeva conducted a systematic review of 38 studies (including 27 case reports) and found that both biologic monotherapy and combination therapy were associated with improved outcomes in SJS/TEN [ 25 ].…”

Section: Managementmentioning

confidence: 99%

A Review of the Systemic Treatment of Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis

et al. 2022

View full text Add to dashboard Cite

Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are uncommon but life-threatening diseases mostly caused by drugs. Although various systemic immunomodulating agents have been used, their therapeutic efficacy has been inconsistent. This study aimed to provide an evidence-based review of systemic immunomodulating treatments for SJS/TEN. We reviewed 13 systematic review and meta-analysis articles published in the last 10 years. The use of systemic corticosteroids and IVIg is still controversial. An increasing number of studies have suggested the effectiveness of cyclosporine and biologic anti-TNF-α in recent years. There were also some promising results of combination treatments. Further large-scale randomized controlled trials are required to provide more definitive evidence of the effectiveness of these treatments. The pathogenesis of SJS/TEN has been elucidated in recent years and advances in the understanding of SJS/TEN may inspire the discovery of potential therapeutic targets.

show abstract

Methazolamide‐induced toxic epidermal necrolysis in a man carrying HLA‐B*59:01: successful treatment with infliximab and glucocorticoid

Cited by 10 publications

References 10 publications

Biologic TNF-α Inhibitors for Stevens–Johnson Syndrome, Toxic Epidermal Necrolysis, and TEN-SJS Overlap: A Study-Level and Patient-Level Meta-Analysis

Biologic TNF-α Inhibitors for Stevens–Johnson Syndrome, Toxic Epidermal Necrolysis, and TEN-SJS Overlap: A Study-Level and Patient-Level Meta-Analysis

Association of HLA-C*01:02 with methazolamide-induced toxic epidermal necrolysis

A Review of the Systemic Treatment of Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis

Contact Info

Product

Resources

About